Randomized Phase II Study of Carboplatin and Etoposide With or Without the bcl-2 Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103

PURPOSE: To assess the efficacy and toxicity of carboplatin, etoposide, and the bcl-2 antisense oligonucleotide oblimersen as initial therapy for extensive-stage small-cell lung cancer (ES-SCLC). bcl-2 has been implicated as a key factor in SCLC oncogenesis and chemotherapeutic resistance. PATIENTS...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Rudin, Charles M., Salgia, Ravi, Wang, Xiaofei, Hodgson, Lydia D., Masters, Gregory A., Green, Mark, Vokes, Everett E.
Format: Artigo
Langue:Inglês
Publié: 2008
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3715075/
https://ncbi.nlm.nih.gov/pubmed/18281659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2007.14.3461
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires